13F reference period
Q2 2026
Security Snapshot
Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) Institutional Ownership
CUSIP: 00439U104
13F Institutional Holders and Ownership History from Q3 2024 to Q3 2026
Institutions Reporting
33
Shares (Excl. Options)
3.85M
Full value: 3,849,792 · shares · 30 Jun 2026Price
$2.27
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- GRCE on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 3,849,792
- Total 13F value
- $8,738,412
- Portfolio coverage rank
- 0%
- Share change
- -418,080
- Value change
- -$4,035,492
- Number of holders
- 33
- Shares outstanding
- 18,244,606
- SEC-reported price per share
- $1.99
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- GRCE - Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 00439U104.
- 33 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 34 to 33 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$19.74M
Full value: $19,744,993 · USD · 31 Mar 2026.$8.74M
Full value: $8,738,412 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 33 institutions filings for Q2 2026.
Security key
00439U104
13F reference period
Q2 2026
13F holders
33
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
GRCE full holder history
Grace Therapeutics, Inc. SEC filings
Grace Therapeutics, Inc. company facts
Grace Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00439U104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
GRCE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 13% | $6,238,850 | 2,748,392 | Opaleye Management Inc. | 05 Aug 2026 | |||
| ADAR1 Capital Management, LLC | 9.9% | 0% | $4,100,110 | +$201,553 | 1,806,216 | +5.2% | ADAR1 Capital Management, LLC | 30 Jun 2026 |
| Nantahala Capital Management, LLC | 6.8% | -32% | $2,674,521 | -$927,195 | 1,178,203 | -26% | Nantahala Capital Management, LLC | 30 Jun 2026 |
| HIRSCHMAN ORIN | 5.9% | -40% | $3,157,115 | -$1,444,764 | 907,217 | -31% | Orin Hirschman | 31 Dec 2025 |
As of 30 Jun 2026,
33
institutional investors reported holding
shares of
Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE).
This represents
21%
of the company’s total
outstanding shares.
3.85M
Full value: 3,849,792 · shares · 30 Jun 202618.24M
Full value: 18,244,606 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
21%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Cerity Partners LLC | 4.7% | 849,055 | 0% | 0% | $1,927,355 |
| Eversept Partners, LP | 4.2% | 772,900 | +2.2% | 0.1% | $1,754,483 |
| BANK OF AMERICA CORP /DE/ | 2.7% | 494,698 | -0.01% | 0% | $1,122,964 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.3% | 411,714 | +2.5% | 0% | $934,591 |
| CITADEL ADVISORS LLC | 1.9% | 349,740 | +254% | 0% | $793,910 |
| Maven Securities LTD | 1.1% | 200,000 | 0.03% | $454,000 | |
| Birchview Capital, LP | 0.66% | 120,000 | +140% | 0.13% | $272,400 |
| CANTOR FITZGERALD, L. P. | 0.55% | 100,000 | 0% | $227,000 | |
| TWO SIGMA INVESTMENTS, LP | 0.53% | 96,890 | 0% | $219,940 | |
| JANE STREET GROUP, LLC | 0.49% | 89,442 | -46% | 0% | $203,034 |
| XTX Topco Ltd | 0.39% | 71,668 | +14% | 0% | $162,686 |
| HRT FINANCIAL LP | 0.34% | 62,691 | 0% | $142,000 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.27% | 49,577 | 0% | $112,540 | |
| BlackRock, Inc. | 0.21% | 37,535 | 0% | $85,205 | |
| Rangeley Capital, LLC | 0.14% | 26,000 | 0.06% | $59,020 | |
| KESTRA PRIVATE WEALTH SERVICES, LLC | 0.13% | 23,000 | +77% | 0% | $52,210 |
| UBS Group AG | 0.09% | 16,777 | -36% | 0% | $38,084 |
| Stratos Investment Management, LLC | 0.06% | 11,158 | 0% | $25,329 | |
| BNP PARIBAS FINANCIAL MARKETS | 0.06% | 10,500 | 0% | 0% | $23,835 |
| Scientech Research LLC | 0.06% | 10,184 | 0.02% | $23,118 | |
| Virtu Financial LLC | 0.06% | 10,166 | 0% | $23,000 | |
| OPPENHEIMER & CO INC | 0.05% | 10,000 | 0% | 0% | $22,700 |
| MORGAN STANLEY | 0.05% | 9,448 | +108% | 0% | $21,447 |
| VANGUARD FIDUCIARY TRUST CO | 0.05% | 8,750 | 0% | 0% | $19,863 |
| NATIONAL BANK OF CANADA /FI/ | 0.01% | 2,680 | -1.3% | 0% | $6,084 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
9
Headline period
Q2 2026
Rows shown
1-9 of 9
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 33,183 | $71,344 | $2.15 | 5 | |
| 2026 Q2 | 3,849,792 | $8,738,412 | -$4,035,492 | $2.27 | 33 |
| 2026 Q1 | 4,264,472 | $19,744,993 | +$1,574,724 | $4.63 | 34 |
| 2025 Q4 | 4,327,617 | $14,995,992 | +$2,269,248 | $3.46 | 22 |
| 2025 Q3 | 3,706,227 | $11,033,102 | -$328,360 | $2.98 | 20 |
| 2025 Q2 | 3,816,908 | $11,344,205 | -$607,725 | $2.97 | 20 |
| 2025 Q1 | 4,024,092 | $9,168,718 | +$4,408,642 | $2.28 | 17 |
| 2024 Q4 | 2,087,877 | $7,835,456 | +$4,246,540 | $3.74 | 15 |
| 2024 Q3 | 959,571 | $2,878,713 | +$2,878,713 | $3.00 | 1 |